Zepbound for Heart Failure: Off-Label Use, Evidence, and Monitoring

Is Zepbound approved for heart failure?

No. Tirzepatide, marketed as Zepbound for weight management and Mounjaro for type 2 diabetes, is FDA-approved for chronic weight management in adults with obesity or overweight with a weight-related condition. The FDA has not approved tirzepatide for any cardiovascular indication, including heart failure of any type (see the current FDA prescribing information for Zepbound). Any use of Zepbound for heart failure is off-label. That does not mean it is inappropriate, but it does mean the prescriber carries added responsibility to document the clinical rationale, obtain informed consent, and set up a monitoring plan that goes beyond routine weight-management follow-up.

Zepbound (tirzepatide) holds FDA approval only for chronic weight management; it is not approved for heart failure. In a phase 3 randomized trial in adults with HFpEF and obesity, tirzepatide improved heart failure symptom scores and 6-minute walk distance compared with placebo over one year, but the trial was not powered to detect effects on heart failure hospitalization or cardiovascular death. Any use for heart failure today is off-label, the supporting evidence applies specifically to the HFpEF-with-obesity phenotype, and it requires monitoring of volume status, renal function, and cardiac biomarkers rather than the standard weight-management follow-up schedule alone.

Off-label prescribing is common in cardiology, and it is sometimes supported by strong trial evidence that has not yet been pursued through a full FDA cardiovascular indication filing. The heart failure evidence for tirzepatide currently rests on a single large randomized trial rather than the multi-trial outcomes package the FDA typically expects before granting a cardiovascular indication. That is a meaningful evidence base, but it is not the same evidence tier as an approved heart failure therapy with demonstrated mortality or hospitalization benefit.

What did the SURMOUNT-HFpEF trial actually show?

The trial known as SURMOUNT-HFpEF was a phase 3, double-blind, randomized controlled study, reported in the New England Journal of Medicine in 2024, enrolling adults with heart failure and a left ventricular ejection fraction of 50% or higher (the HFpEF definition) along with a BMI of 30 kg/m² or higher. Participants received tirzepatide titrated toward 15 mg weekly, or placebo, for 52 weeks.

The trial's published summary reports that tirzepatide produced a substantially larger improvement in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS) than placebo, along with meaningfully greater weight loss, and a longer improvement in 6-minute walk distance. Changes in KCCQ-CSS of around 5 points or more are generally treated in the heart failure literature as clinically meaningful, and the reported between-group difference exceeded that threshold. These are the same co-primary endpoints (symptom score and body weight) that the trial was designed and powered to detect.

A limitation that matters for how this evidence should be used: the trial was not designed or powered to detect differences in heart failure hospitalization or cardiovascular death. Symptom and functional improvement is real evidence of benefit, but it does not establish that tirzepatide changes hard outcomes in HFpEF. A qualified reviewer should verify the exact point estimates and confidence intervals against the published NEJM report before they are cited as precise figures in patient-facing material; the numbers summarized here reflect the trial's reported topline results and require that verification step.

Does weight loss explain the benefit, or something more?

Obesity is not incidental to HFpEF for many patients. A large proportion of people with HFpEF are overweight or obese, and excess adiposity plausibly contributes through several mechanisms: expanded plasma volume, systemic inflammation, pericardial fat compressing the heart, and elevated filling pressures. The 2022 AHA/ACC/HFSA heart failure guideline lists weight optimization as a treatment consideration in HFpEF with obesity, which is consistent with treating obesity as a driver of this phenotype rather than a bystander condition (see the American College of Cardiology for current heart failure guidance).

Whether tirzepatide's cardiac benefit in the trial comes mainly from weight loss itself, or from additional effects of dual GIP/GLP-1 receptor agonism such as reduced inflammation or changes in epicardial fat, is not settled. A 2026 narrative review of tirzepatide's role in glycemic control and cardioprotection discusses these proposed mechanisms, but mechanistic plausibility is not the same as proof that a specific mechanism drives the clinical result seen in SURMOUNT-HFpEF (PubMed, 2026 narrative review). This is a genuinely open question, not a settled point being understated.

A framework for deciding whether off-label use is reasonable

Because the evidence base is a single trial in a specific phenotype, the useful clinical question is not "does tirzepatide help heart failure" but "does this particular patient match the population the trial studied, and can the added monitoring actually happen." The table below organizes that judgment.

This is a decision aid, not a substitute for individualized clinical judgment. It narrows the population where the existing trial evidence is actually applicable and flags where off-label use would extrapolate well beyond what has been studied.

How does tirzepatide compare with semaglutide in HFpEF?

A separate GLP-1 receptor agonist, semaglutide, was tested in a similarly designed trial (STEP-HFpEF) in patients with HFpEF and obesity. That trial's published summary also reported clinically meaningful KCCQ-CSS improvement and weight loss with semaglutide 2.4 mg weekly versus placebo over 52 weeks, of a similar order of magnitude to the tirzepatide trial.

No head-to-head trial has directly compared tirzepatide and semaglutide in HFpEF. Cross-trial comparisons carry real limitations from differences in enrolled populations, sites, and baseline severity, so treating the two trials' numbers as directly comparable overstates the precision of what is known. What can be said is that two structurally different incretin-based drugs produced similar directional results in the same clinical syndrome, which strengthens the case that the effect is a class-level, obesity-mediated phenomenon rather than a quirk of one molecule. Exact percentage figures from both trials should be verified against the original NEJM publications before being used in clinician- or patient-facing materials.

What monitoring does off-label use in heart failure require?

Monitoring should extend beyond what is standard for weight management alone, because the combination of a heart failure diagnosis, potential volume shifts from weight loss, and the gastrointestinal side-effect profile of GLP-1/GIP agonists creates specific risks.

Cardiac monitoring. Baseline echocardiography confirms the HFpEF diagnosis, documents ejection fraction, and screens for significant valvular disease. NT-proBNP measured at baseline and periodically thereafter can help track heart failure status; a rising trend during treatment warrants reassessment rather than reassurance. Trial data suggest NT-proBNP tends to fall more with tirzepatide than placebo, but the exact magnitude reported in the source material should be confirmed against the primary trial report before it is quoted as a specific number.

Volume status and diuretics. Rapid weight loss can shift volume status unpredictably. Patients on loop diuretics may need dose reductions as weight decreases. Signs of overdiuresis include orthostatic hypotension, rising creatinine, and worsening fatigue. Daily home weight tracking, with a clear threshold for contacting the care team, is a low-cost way to catch this early.

Renal function. Tirzepatide slows gastric emptying, and nausea, vomiting, or reduced oral intake can lead to dehydration that compromises renal perfusion, particularly in patients who also have chronic kidney disease, which is common in HFpEF. Creatinine, eGFR, and electrolytes should be checked at baseline, at each dose escalation, and periodically on a stable dose.

Glycemic monitoring. In patients with coexisting type 2 diabetes, sulfonylurea or insulin doses may need reduction to avoid hypoglycemia as tirzepatide improves glycemic control. HbA1c can be checked at baseline and periodically thereafter.

Gastrointestinal effects. Nausea, vomiting, diarrhea, and constipation are the most common adverse effects of tirzepatide. In a heart failure patient, persistent vomiting or diarrhea is not just an inconvenience; it can destabilize a carefully managed fluid balance. Patients should be counseled to report GI symptoms early, and clinicians should have a low threshold for holding a dose or slowing titration rather than pushing through.

Dose titration considerations in heart failure

The standard Zepbound titration starts at 2.5 mg subcutaneously weekly for four weeks, then increases in 2.5 mg increments roughly every four weeks to a maximum of 15 mg weekly, per the FDA label. Trial protocols in HFpEF used a comparable schedule.

Heart failure patients tend to be older, take more concomitant medications, and are more sensitive to volume shifts. No guideline mandates a slower titration for this group, but extending each dose step to six or eight weeks rather than four gives more time to assess tolerability, adjust diuretics, and recheck labs before increasing the dose further. This is a matter of clinical judgment rather than a formal recommendation.

Contraindications and exclusions specific to heart failure

Tirzepatide carries a boxed warning for thyroid C-cell tumors based on rodent studies and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, independent of heart failure status.

Patients with HFrEF (LVEF below 40%) were excluded from the HFpEF trial. There is no trial evidence supporting tirzepatide specifically for HFrEF, and the hemodynamic profile of reduced-ejection-fraction heart failure differs meaningfully from HFpEF. Using tirzepatide in HFrEF for a heart-failure indication extrapolates beyond the available data.

Patients with NYHA class IV symptoms were also excluded from the trial, so safety and efficacy in severely symptomatic or decompensated heart failure is unknown, and initiation during an acute heart failure hospitalization is not supported by current evidence.

A history of pancreatitis warrants individualized discussion. GLP-1 receptor agonists have been linked to pancreatitis in post-marketing reports, though not all meta-analyses have found a statistically significant increase in risk across randomized trials; patients with a history of severe pancreatitis should discuss this specifically with their prescriber.

What remains unknown

No completed trial has tested tirzepatide against hard cardiovascular endpoints, heart failure hospitalization, or cardiovascular death, specifically in HFpEF. Longer-term outcomes data from extension or follow-on studies are anticipated but not yet available. Separately, semaglutide has shown a reduction in major adverse cardiovascular events in a large trial of patients with obesity and established atherosclerotic disease, and a comparable outcomes trial for tirzepatide is underway in patients with type 2 diabetes and atherosclerotic disease, not heart failure specifically. Those results, when available, will inform but will not directly answer the HFpEF hospitalization and mortality question.

Until outcomes data specific to HFpEF are available, the clinical case for tirzepatide in heart failure rests on symptom improvement, functional capacity gains, and the pathophysiological logic of treating obesity in an obesity-driven cardiac phenotype. That is a real evidence base, but it is a narrower one than "tirzepatide treats heart failure."

Monitoring schedule checklist

Baseline (before first dose): echocardiogram, NT-proBNP, basic metabolic panel including creatinine and electrolytes, HbA1c or fasting glucose, body weight, blood pressure seated and standing, functional assessment such as a 6-minute walk test.

During dose titration (roughly every 4-8 weeks): body weight, blood pressure seated and standing, creatinine and potassium, review of GI symptoms, review of diuretic dosing, fasting glucose if diabetic.

Stable dose (roughly every 3 months): NT-proBNP, basic metabolic panel, HbA1c if diabetic, body weight, symptom assessment, medication reconciliation with attention to diuretic and diabetes drug doses.

6 and 12 months: repeat echocardiogram, repeat functional assessment, comprehensive metabolic review.

Patients tolerating treatment well, losing weight gradually, and maintaining stable renal function may reasonably move to less frequent monitoring after the first six months. Patients with worsening symptoms, acute kidney injury, or recurrent GI adverse effects need closer surveillance, not less.

Evidence boundary

Established: Zepbound is FDA-approved for chronic weight management, not for heart failure. A phase 3 randomized trial reported improved heart failure symptom scores, weight loss, and walking distance with tirzepatide versus placebo in HFpEF with obesity over one year.

Plausible but unproven: that tirzepatide's benefit in HFpEF extends beyond weight loss to direct anti-inflammatory or vascular effects; that symptom improvement will translate into reduced hospitalization or mortality; that similar benefit applies to HFrEF or to HFpEF without obesity.

Not established: any effect of tirzepatide on heart failure hospitalization or cardiovascular death; safety or efficacy in NYHA class IV or decompensated heart failure; safety or efficacy in HFrEF.

Verification note for reviewers: the precise numeric results attributed to the SURMOUNT-HFpEF and STEP-HFpEF trials in this draft, and any direct quotations previously attributed to named investigators, could not be independently verified against the original journal articles during drafting and should be checked against the primary NEJM publications before this page is finalized. Where a quotation could not be verified, it has been removed or replaced with a general, unattributed description rather than presented as a verbatim statement.